Sisram Medical Ltd. (HK:1696)
:1696
Want to see HK:1696 full AI Analyst Report?
Top Page
Sisram Medical Ltd.
(1696)
Select Model
Select Model
Rating:61Neutral
Price Target:
HK$3.00
▼(-22.48% Downside)
Action:Reiterated
Date:05/21/26
The score is driven primarily by mixed fundamentals: a strong, low-leverage balance sheet is offset by significant margin compression and notably weaker 2025 operating/free cash flow. Technicals are a major drag due to a clear downtrend and bearish momentum, while valuation provides partial support with a moderate P/E and a ~4.5% dividend yield.
Positive Factors
Conservative balance sheet
Low leverage and an expanding equity base give Sisram durable financial flexibility to fund product development, maintain service networks and absorb demand cycles typical in medical devices. This reduces refinancing risk and supports strategic investments without stressing cash flows.
Negative Factors
Net margin compression
A decline from double-digit to low single-digit net margins suggests persistent margin pressure from pricing competition or higher operating costs. That erosion limits free cash flow conversion and the company's ability to fund growth initiatives, dividends, or buybacks sustainably.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage and an expanding equity base give Sisram durable financial flexibility to fund product development, maintain service networks and absorb demand cycles typical in medical devices. This reduces refinancing risk and supports strategic investments without stressing cash flows.
Read all positive factors
Sisram Medical Ltd. (1696) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.31B
Dividend Yield2.82%
Average Volume (3M)469.37K
Price to Earnings (P/E)5.0
Beta (1Y)1.14
Revenue Growth4.57%
EPS Growth-24.35%
CountryHK
Employees1,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.04
Shares Outstanding468,343,080
10 Day Avg. Volume515,040
30 Day Avg. Volume469,367
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)0.53
Price to Sales (P/S)0.69
P/FCF Ratio37.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.50Price Target Upside16.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.48
Revenue Forecast (FY)HK$3.22B
Sisram Medical Ltd. Business Overview & Revenue Model
Company Description
Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical, minimally invasive treatment systems, and non-energy based devices and cosmeceuticals in the Asia Pacific, Europe, North ...
How the Company Makes Money
Sisram Medical makes money primarily by selling medical aesthetic systems (capital equipment) and by generating recurring revenue tied to the installed base of those systems. Key revenue streams typically include: (1) Sales of energy-based aesthet...
Sisram Medical Ltd. Financial Statement Overview
Summary
Income Statement
67
Positive
Balance Sheet
82
Very Positive
Cash Flow
49
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 345.86M | 365.35M | 349.11M | 359.29M | 354.48M | 294.29M |
| Gross Profit | 210.72M | 215.14M | 216.68M | 219.53M | 202.23M | 166.86M |
| EBITDA | 33.03M | 38.22M | 38.91M | 53.43M | 58.38M | 55.96M |
| Net Income | 20.60M | 19.02M | 25.13M | 31.50M | 40.17M | 31.25M |
Balance Sheet | ||||||
| Total Assets | 633.26M | 657.17M | 627.26M | 613.50M | 555.60M | 530.13M |
| Cash, Cash Equivalents and Short-Term Investments | 62.01M | 70.96M | 71.98M | 70.60M | 91.49M | 157.96M |
| Total Debt | 46.97M | 51.75M | 43.20M | 44.68M | 41.34M | 41.62M |
| Total Liabilities | 145.56M | 153.55M | 142.47M | 143.98M | 123.38M | 126.51M |
| Stockholders Equity | 466.38M | 479.79M | 464.03M | 452.31M | 430.87M | 402.18M |
Cash Flow | ||||||
| Free Cash Flow | 20.87M | 6.82M | 30.38M | 35.37M | -42.28M | 29.41M |
| Operating Cash Flow | 24.23M | 9.40M | 33.08M | 43.94M | 22.04M | 32.38M |
| Investing Cash Flow | -17.64M | -1.70M | -6.59M | -32.99M | -52.11M | -46.77M |
| Financing Cash Flow | -18.79M | -10.92M | -16.11M | -20.97M | -17.85M | 55.78M |
Sisram Medical Ltd. Technical Analysis
Negative
3.87
Price Trends
3.22
Negative
3.72
Negative
4.44
Negative
Market Momentum
-0.12
Negative
40.72
Neutral
33.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1696, the sentiment is Negative. The current price of 3.87 is above the 20-day moving average (MA) of 2.92, above the 50-day MA of 3.22, and below the 200-day MA of 4.44, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 40.72 is Neutral, neither overbought nor oversold. The STOCH value of 33.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1696.
Sisram Medical Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$757.19M | 11.17 | 5.68% | 3.48% | -3.30% | 6.27% | |
61 Neutral | HK$1.31B | 5.03 | 4.02% | 2.82% | 4.57% | -24.35% | |
57 Neutral | HK$415.19M | 11.85 | 4.12% | ― | 2.17% | 109.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$3.49B | -6.72 | -11.27% | ― | 16.35% | 9.84% | |
49 Neutral | HK$160.74M | -2.82 | -17.70% | ― | -38.20% | -108.24% | |
43 Neutral | HK$582.14M | -2.30 | -21.29% | ― | -34.96% | 42.74% |
* Healthcare Sector Average
HK:1696
Sisram Medical Ltd.
2.93
-1.12
-27.65%
HK:9996
Peijia Medical Ltd.
5.31
-0.49
-8.45%
HK:2393
Yestar Healthcare Holdings Co Ltd
0.07
-0.03
-28.00%
HK:2407
Gaush Meditech Ltd.
5.24
-0.54
-9.34%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.35
-1.24
-47.88%
HK:6118
Austar Lifesciences Ltd.
0.80
0.11
15.94%
Sisram Medical Ltd. Corporate Events
Sisram Medical Sets June 2026 AGM to Seek Share Repurchase and Issuance Mandates
May 19, 2026
Sisram Medical Ltd. has convened its annual general meeting for 24 June 2026 in Hong Kong, where shareholders will review the audited financial statements for the year ended 31 December 2025 and consider the re-election of four directors, includin...
Sisram Medical Completes Internal Shareholding Reorganisation Under Fosun Pharma
Apr 22, 2026
Sisram Medical has announced the completion of a reorganisation at the controlling shareholder level involving internal transfers of its shares among Fosun Pharma’s indirect wholly owned subsidiaries. Ample Up and Chindex have transferred th...
Fosun Pharma Streamlines 71.42% Stake in Sisram Medical Through Internal Reorganisation
Apr 8, 2026
Sisram Medical Ltd. announced a planned internal reorganisation at its controlling shareholder Fosun Pharma, under which two indirect wholly owned subsidiaries, Ample Up Limited and Chindex Medical Limited, will transfer their entire combined 71.4...
Sisram Medical Declares Final Cash Dividend for 2025
Mar 24, 2026
Sisram Medical Ltd. has declared a final ordinary cash dividend of HKD 0.095 per share for the financial year ended 31 December 2025, with all key timetable details such as ex-dividend date, record date, payment date, and applicable withholding ta...
Sisram Medical Grows Revenue on Injectables Boom but Margins Tighten in 2025
Mar 23, 2026
Sisram Medical reported 2025 revenue of US$365.3 million, up 4.7% year on year, driven notably by a 185.6% surge in injectables revenue to US$28.0 million and solid 20.1% growth in international markets outside North America. Despite this top-line...
Sisram Medical Sets US$11.2 Million Annual Caps on Royalty Payments to Fosun Affiliate
Mar 12, 2026
Sisram Medical has set annual caps of up to USD11.2 million for royalty payments to Fosun Industrial under a sublicense agreement covering a licensed product it plans to commercialise from 2026, with the caps applying to each of the financial year...
Sisram Medical Sets March 2026 Board Meeting to Approve 2025 Results
Mar 6, 2026
Sisram Medical has scheduled a board meeting for 23 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2025. The board will also consider recommending a final dividend and may address other c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.